{"analyses":[{"ciNumSides":"TWO_SIDED","ciPctValue":"95","groupDescription":"The number of courses of therapy delivered or patients randomized to Regimen B - RA + Immunotherapy and non-randomly assigned to Regimen B after halting of randomization, excluding patients with persistent disease, were compared using the Wilcoxon rank-sum test.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0262","paramType":"Mean Difference (Net)","paramValue":"0","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"6","value":"6"}]}],"title":"Randomized to Regimen B - RA + Immunotherapy"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"6","value":"6"}]}],"title":"Non-randomly assigned after halting randomization"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1291"}],"units":"Participants"}],"description":"Number of courses of therapy delivered for patients randomized to RA + Immunotherapy vs. patients non-randomly assigned to RA + Immunotherapy, excluding patients with persistent disease.","dispersionType":"Full Range","groups":[{"description":"Regimen B- RA + Immunotherapy","id":"OG000","title":"Regimen B"}],"paramType":"MEDIAN","populationDescription":"Eligible patients assigned to Regimen B, excluding patients with persistent disease.","reportingStatus":"POSTED","timeFrame":"Courses 1-6","title":"Number of Courses of Therapy Delivered","type":"SECONDARY","unitOfMeasure":"courses per patient"}